AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 SEP 12 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - An anti-idiotypic monoclonal antibody vaccine against chlamydia protects mice from infectious challenge with a human urogenital strain of Chlamydia trachomatis, according to a new report in Vaccine.
The finding suggests a possible new avenue for chlamydia vaccine research, which has yielded little new information in the past three decades, said J.A. Whittum-Hudson and colleagues in the United States.
"No vaccine candidate has protected against heterologous challenge, nor at more than one site of infection," they pointed out. "The majority of experimental anti-chlamydial vaccines to date have targeted the chlamydial major outer membrane protein (MOMP). Many MOMP-directed vaccine candidates have been highly immunogenic, but have failed to protect against infectious challenge."
Whittum-Hudson and team turned their attention to a different antichlamydial vaccine, a monoclonal anti-idiotypic antibody (anti-Id; mAb2), which is a molecular mimic of the chlamydial glycolipid exoantigen (GLXA).
When C3H/HeJ mice were vaccinated with either mucosal (oral or intranasal) or systemic (subcutaneous) poly (lactide) encapsulated mAb2 to GLXA, they were significantly protected against topical vaginal challenge with C. trachomatis (K serovar; UW-31), reported Whittum-Hudson and coworkers. Reduced vaginal shedding of C. trachomatis and less genital ...
Source: HighBeam Research, GLXA-directed Antibody Protects Mice From Human C. Trachomatis.(Brief...